Restasis for Treatment of Brittle Nails

This study has been completed.
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Julian M. Mackay-Wiggan, Columbia University
ClinicalTrials.gov Identifier:
NCT00986427
First received: September 29, 2009
Last updated: July 17, 2013
Last verified: July 2013
  Purpose

This purpose of this study is to assess the safety and effectiveness of Restasis® ophthalmic emulsion versus emulsion alone( Refresh Dry Eye therapy) both for the treatment of brittle nails and for the enhancement of normal nail growth and texture. The investigators think that daily application of Restasis® to nails and nail beds in patients with brittle nails will enhance nail growth and improve nail texture in both affected and unaffected nails.


Condition Intervention Phase
Brittle Nails
Drug: Restasis (cyclosporine ophthalmic emulsion) 0.05%
Drug: Refresh® Dry Eye therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Restasis® Ophthalmic Emulsion for the Treatment of Brittle Nails

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Change From Baseline in the Physician's Global Assessment (PGA) of Target Fingernails #1 and #2 [ Time Frame: Baseline, week 24 ] [ Designated as safety issue: No ]

    Change from baseline in the Physician's Global Assessment (PGA) of target fingernails #1 and #2 as measured at week 24.

    The PGA is a static evaluation/measure of the severity of brittle nails signs in target fingernails #1 and #2 (the 2 nails with the most severe signs of brittleness). Evaluated sings were the degree of lamellar onychoschizia, ridging, longtitudinal splitting, fragility/breakage and thickness. The PGA was scored on a 6 point scale from 0 to 5, in which 0 = none, 1 = mild, 2 = mild to moderate, 3 = moderate, 4 = moderate to severe, 5 = severe. A negative number change from baseline (decrease in grade score) indicates improvement and a positive change (increase in grade score) indicates worsening.



Secondary Outcome Measures:
  • Change From Baseline in Quality of Life (QOL) Related to Nail Disease [ Time Frame: Baseline, week 24 ] [ Designated as safety issue: No ]
    Change from baseline in quality of life as measured at week 24 by the subject satisfaction Questionnaire question: "Overall, how satisfied are you with your nails?" Responses ranged from 1 (very satisfied) to 5 (very unsatisfied). A negative number changed from baseline (decrease in grade score) indicates improvement and a positive change (increase in grade score) indicates worsening.

  • Growth of the Treated and Untreated Nail in the Previous 4 Weeks [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    Growth of the treated and untreated nail the previous 4 weeks. Nail growth was measured in millimeters.

  • Number of Subjects Achieving Improvement in the Physician's Global Improvement Assessment (PGIA) [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    Number of subjects achieving improvement in the PGIA. The investigator assessed the two target fingernails with a rating of Excellent, Good, Fair, No Improvement or Worse based on the comparison between the nails at the current visit and high-resolution photographs of the nails taken at baseline. An improvement was a score of Excellent/Good/Fair vs. No Improvement/Worse.


Enrollment: 24
Study Start Date: July 2009
Study Completion Date: December 2012
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
Drug: Restasis (cyclosporine ophthalmic emulsion) 0.05%
cyclosporine ophthalmic emulsion 0.05%
Other Name: Restasis®
Placebo Comparator: 2
Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
Drug: Refresh® Dry Eye therapy
Emulsion contains glycerin 1% and polysorbate 80
Other Name: Refresh®

Detailed Description:

This is a single center, investigator-blinded (investigator masked), head to head comparison of Restasis® and its vehicle, Refresh® Dry Eye Therapy in 24 patients. Three target fingernails will be identified in each subject. Two of the target nails will be the two nails that have the most severe signs of brittle nail syndrome. The third target nail will be a normal nail or, in the absence of a normal nail, the patient's second-healthiest appearing nail. The patients most normal-appearing nail will be untreated so that growth in the treated nails can be compared to growth in an untreated normal nail, this will be the fourth target nail. Study medication will be applied to target nails (the subjects may also apply to all nails if they wish, except one nail which will be untreated in order to determine the subject's baseline rate of fingernail growth) for 24 weeks. The target nails will be assessed at each visit, every four weeks. There will be a 12-week follow up period after treatment is completed.

This 36 week study will be conducted at one center. Adult male and female patients meeting the inclusion and exclusion criteria will be screened for eligibility. The principal investigator or his/her designee will obtain informed consent from all patients before any protocol specific procedures are performed.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • must have IRB approved written informed consent prior to participating in any study related procedures
  • Must be a male or female patient 18 to 75 years of age
  • must have a diagnosis of brittle or meet the criteria for a diagnosis of brittle nails at the screening visit based on at least two of the following signs and symptoms of brittle nails in each of the selected nail plates or severe signs (one or more) on each target nail
  • trachyonychia (surface roughness)
  • lamellar onychoschizia (horizontal layering/peeling
  • longitudinal cracking or splitting of the distal edge (raggedness)
  • must have two fingernails with brittle nail signs and symptoms identified at baseline
  • must have two normal or near-normal nails on the same hand
  • female patients of childbearing potential (not surgically sterile or at least 2 years postmenopausal) must have a negative pregnancy at baseline/day 1 and may not be lactating
  • sexually active female subjects who are not surgically sterile or 2 years post menopausal must agree to use contraception/birth control measure while on study (e.g., oral contraceptive, diaphragms with spermicide, condoms with spermicide, intrauterine devices, Norplant System, Depo-Provera, tubal ligation). Monthly urine pregnancy tests will be administered to women of childbearing potential
  • must agree to self administer topical study medication, and must agree to complete all study procedures
  • must be judged to be in good health by medical history and physical examination
  • must be able to adhere to the study visit schedule and other protocol requirements, including avoiding the use of nail polish, adhesive nails, and manicures for the duration of the study

Exclusion Criteria:

  • have a history of surgery of the affected fingernails
  • are chronic nail biters
  • are pregnant, nursing, or planning pregnancy prior to study enrollment
  • have a disturbance of the shape of the affected fingernails (e.g., due to malformation of the underlying bone) that would interfere with the investigator's ability to evaluate photographs or nail changes
  • have onycholysis (lifting of the nail plate off the nail bed) of the affected fingernails
  • have signs of a fungal or bacterial infection of the affected fingernails
  • have a history of psoriasis or lichen planus involving any nail, or active contact dermatitis involving the affected fingernails
  • have used any topical cosmetics or medicated products on the affected nails within 2 weeks of baseline visit
  • have received oral antifungal treatment within 3 months of baseline visit
  • have a known or suspected history of a genetic condition affecting the nails (e.g., Darier's disease, nail-patella syndrome, tuberous sclerosis)
  • have used any investigational drug within the previous 1 month or 5 half-lives of the investigational agent, whichever is longer, or 3 months for any biologic of unknown half-life
  • are known or suspected to have had a substance abuse (drug or alcohol) problem within the previous 3 years
  • is unlikely to comply with the study protocol and prescribed treatment or is unsuitable for any other reason in the opinion of the investigator
  • chronic liver, heart, kidney, or (untreated) thyroid disease
  • have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease
  • currently have any known malignancy or have a history of malignancy other than non-melanoma skin cancer
  • have signs of bacterial, fungal or viral skin lesions that may interfere with evaluation of the target nails
  • known sensitivity to any active or inactive ingredient in Restasis(R) or Refresh(R) Dry Eye Therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00986427

Locations
United States, New York
Columbia University Medical Center Department of Dermatology
New York, New York, United States, 10032
Sponsors and Collaborators
Julian M. Mackay-Wiggan
Allergan
Investigators
Principal Investigator: Julian Mackay Wiggan, MD, MS Columbia University Medical Center Department of Dermatolgoy
  More Information

No publications provided

Responsible Party: Julian M. Mackay-Wiggan, Assistant Clinical Professor of Dermatology, Columbia University
ClinicalTrials.gov Identifier: NCT00986427     History of Changes
Other Study ID Numbers: AAAD9927, Res-01-2009
Study First Received: September 29, 2009
Results First Received: May 10, 2013
Last Updated: July 17, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cyclosporine
Cyclosporins
Glycerol
Anti-Infective Agents
Antifungal Agents
Antirheumatic Agents
Cryoprotective Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014